

Adopted as Rule: September 30, 2013

Toxicological Summary for Naphthalene: CAS: 91-20-3

Synonyms: Camphor tar; mighty 150; mighty rd1; Mothballs; Moth Flakes; Naphthalene; Naphthalene, crude; Naphthalene; Naphthalene, molten; Naphthene; tar camphor; white tar

Non-Cancer Acute Health Risk Limit ($nHRL_{acute}$) = 70 µg/L

=	(Reference Dose,	mg/kg/d) x	(Relative S	Source (Contribution) x ((Conversion Factor)	L
	(Short-term L/kg/d)							

= <u>(0.038 mg/kg/d) x (0.5) x (1000 µg/mg)</u> (0.289 L/kg-d)

= 66 rounded to 70 µg/L

Reference Dose / Concentration: Source of toxicity value: Point of Departure:	0.038 mg/kg-day (Sprague Dawley rats) MDH, 2011 50 mg/kg-day (LOAEL), (National Toxicology Program (NTP) 1991) developmental gavage study in SD rats (No NOAEL)
Human Equivalent Dose Adjustment: Total uncertainty factor:	11.5 [50 mg/kg-d x 0.23] (MDH, 2011) 300
UF allocation:	
Critical effect(s):	Maternal nervous system effects which included lethargy, shallow breathing and impaired posture
Co-critical effect(s): Additivity endpoint(s):	None

Non-Cancer Short-term Health Risk Limit (nHRL_{short-term}) = 70 µg/L

= <u>(Reference Dose, mg/kg/d) x (Relative Source Contribution) x (Conversion Factor)</u> (Short-term L/kg/d)

> = (0.038 mg/kg/d) x (0.5) x (1000 µg/mg) (0.289 L/kg-d)

> > = 66 rounded to 70 µg/L

Reference Dose / Concentration: Source of toxicity value: Point of Departure:	0.038 mg/kg-day (Sprague Dawley rats) MDH, 2011 50 mg/kg-day (LOAEL), (National Toxicology Program (NTP) 1991) developmental gavage study in SD rats (No NOAEL)			
Human Equivalent Dose Adjustment: Total uncertainty factor:	11.5 [50 mg/kg-d x 0.23] (MDH, 2011) 300			
UF allocation:	3 interspecies extrapolation (toxicodynamics); 10 intraspecies variation; 3 database gaps – lack of 2-generation reproductive toxicity studies and lack of dose-response data for hemolytic anemia and cataract formation which have been observed in human epidemiological studies for naphthalene; 3 LOAEL-to-NOAEL – a default of 10 was not applied because the neurological effects observed did not persist at this dose for the entire length of the NTP study (however the neurological effects did persist at higher doses)			
Critical effect(s):	Maternal nervous system effects which included lethargy, shallow breathing and impaired posture			
Co-critical effect(s): Additivity endpoint(s):	None			

Non-Cancer Subchronic Health Risk Limit (nHRL_{subchronic}) = nHRL_{short-term} = 70 µg/L

= <u>(Reference Dose, mg/kg/d) x (Relative Source Contribution) x (Conversion Factor)</u> (Subchronic L/kg/d)

> = (0.052 mg/kg/d) x (0.2) x (1000 µg/mg) (0.077 L/kg-d)

> > = 135 rounded to 100 μ g/L

Reference Dose / Concentration: Source of toxicity value: Point of Departure:	0.052 mg/kg-day (Fischer 344 rats) MDH, 2011 71 mg/kg-day (NOAEL), (Battelle's Columbus Laboratories (BCL) 1980a) gavage study in F344 rats
Human Equivalent Dose Adjustment: Total uncertainty factor:	15.6 [71 mg/kg-d x 0.22] (MDH, 2011) 300
UF allocation:	
Critical effect(s): Co-critical effect(s):	Decrease in terminal body weight Decreased spleen weight, lethargy, slow breathing, prone body posture, increased rooting behavior, decreased body weight associated with decreased food and water consumption
Additivity endpoint(s):	Nervous system; spleen

The subchronic nHRL must be protective of the short-term exposures that occur within the short-term period and therefore, the subchronic nHRL is set equal to the acute / short-term nHRL of 70 μ g/L. Additivity endpoints: Nervous system

Non-Cancer Chronic Health Risk Limit (nHRL _{chronic}) = 70 μg/L					
= (Reference Dose, mg/kg/d) x (Relative Source Contribution) x (Conversion Factor) (Chronic intake rate, L/kg/d)					
= <u>(0.016 m</u>	= <u>(0.016 mg/kg/d) x (0.2) x (1000 µg/mg)</u> (0.043 L/kg-d)				
	= 74 rounded to 70 μg/L				
Reference Dose / Concentration: Source of toxicity value: Point of Departure: Human Equivalent Dose Adjustment: Total uncertainty factor: UF allocation:	0.016 mg/kg-day (Fischer 344 rats) MDH 2011 71 mg/kg-day (NOAEL), (Battelle's Columbus Laboratories (BCL) 1980a) gavage study in F344 rats 15.6 [71 mg/kg-d x 0.22] (MDH, 2011) 1000 3 interspecies extrapolation (toxicodynamics); 10 intraspecies variation; 10 database gaps – lack of 2-generation reproductive toxicity studies, lack of dose-response data for hemolytic anemia and cataract formation which have been observed in human epidemiological studies for naphthalene, and a lack of neurotoxicity studies in the subchronic and chronic durations; 3 subchronic-to-chronic extrapolation because effects did not increase in severity with increasing exposure duration and most effects were observed within a shorter duration				
Critical effect(s): Co-critical effect(s): Additivity endpoint(s):	Decrease in terminal body weight Decreased spleen weight, lethargy, slow breathing, prone body posture, increased rooting behavior, decreased body weight associated with decreased food and water consumption Nervous system; spleen				

Cancer Health Risk Limit (cHRL) = Not Applicable

Cancer classification:	Group C – there is evidence of carcinogenicity following inhalation
	exposure
Slope factor:	NA
Source of slope factor:	NA
Tumor site(s):	NA
()	

Volatile: Yes (moderate)

Summary of changes since 1993/1994 HRL promulgation:

The acute, short-term, subchronic, and chronic HRLs (70 μ g/L) are 4 times lower than the 1993/94 chronic HRL (300 μ g/L) as the result of: 1) utilizating of more recent intake rate data that incorporates higher intakes early in life, 2) more recent lower RfD values, and 3) rounding to one significant digit. The HRLs were adopted in 2013 and the 1993 HRL was repealed.

	Endocrine	Immunotoxicity	Development	Reproductive	Neurotoxicity
Tested?	No	Yes	Yes	No	Yes
Effects?	-	Yes ¹	Yes ²	Secondary Observation	Yes ³

Summary of toxicity testing for health effects identified in the Health Standards Statute:

Note: Even if testing for a specific health effect was not conducted for this chemical, information about that effect might be available from studies conducted for other purposes. Most chemicals have been subject to multiple studies in which researchers identify a dose where no effects were observed, and the lowest dose that caused one or more effects. A toxicity value based on the effect observed at the lowest dose across all available studies is considered protective of all other effects that occur at higher doses.

Comments on extent of testing or effects:

Note: individuals, particularly, infants, deficient in G6PDH are thought to be especially sensitive to naphthalene-induced hemolytic anemia.

- ¹Decreased spleen weights seen in mice exposed to naphthalene for 14-days and 90-day by gavage (Shopp et al 1984) and it is listed as a co-critical effect for the subchronic and chronic durations. Lymphoid depletion of the thymus was seen in 2/10 female rats exposed to naphthalene by gavage for 13 weeks at 2 times the critical subchronic and chronic LOAEL_{HED}.
- ² Developmental studies were conducted in three species (rats, mice, and rabbits). A reduction in number of live pups per litter were observed at levels approximately 4 times critical acute and short-term LOAEL_{HED} of 11.5 mg/kg-day. Malformations in offspring were observed at an HED of 104 mg/kg-day which is 3 times greater than the critical subchronic and chronic LOAEL_{HED}. No developmental effects were seen in the absence of significant maternal toxicity.
- ³ Neurotoxicity (lethargy, slow breathing) was considered the critical acute and short-term effect. Tolerance to neurological effects developed in low dose groups but persisted at higher doses. Neurological effects are listed as co-critical effects for the subchronic and chronic durations.

References:

- Agency for Toxic Substances and Disease Registry (ATSDR) MRLs. (2009). "Minimal Risk Levels for Hazardous Substances (MRLs)." from <u>http://www.atsdr.cdc.gov/mrls/mrls_list.html</u>.
- Agency for Toxic Substances and Disease Registry (ATSDR) Toxicological Profiles. "Toxicological Profile Information Sheet." from <u>http://www.atsdr.cdc.gov/toxpro2.html</u>.
- Ariyoshi, T., M. Eguchi, et al. (1981). "Effects of chlorinated benzenes of the activities of deltaaminolevulinic acid synthetase and heme oxygenase and on the content of hemoprotein in the liver of rats. (Abstract Only)." J Pharmacobiodyn 4(1): 69-76.

ATSDR Toxicological Profile (2005). Naphthalene.

- Battelle's Columbus Laboratories (BCL) (1980a). Unpublished subchronic toxicity study: Naphthalene (C52904), Fischer 344 rats. -. Prepared by Battelle Laboratories under NTP Subcontract No. 76-34-106002. Available from the Center for Environmental Research Information.
- Battelle's Columbus Laboratories (BCL) (1980b). Unpublished subchronic toxicity study: Naphthalene (C52904), B6C3F1 mice. Prepared by Battelle Laboratories under NTP Subcontract No. 76-34-106002.
- California Environmental Protection Agency-OEHHA Toxicity Criteria Database. from http://www.oehha.ca.gov/risk/ChemicalDB/index.asp.
- California Environmental Protection Agency OEHHA Cancer Potency Values. (2005). "OEHHA Toxicity Criteria Database." from <u>http://www.oehha.ca.gov/risk/pdf/cancerpotalpha81005.pdf</u>.
- California Water Resources Control Board. (2008). "Water Quality Limits for Consituents and Parameters." from <u>http://www.waterboards.ca.gov/water_issues/programs/water_quality_goals/docs/limit_tables_2008</u> <u>.pdf</u>.
- Health Canada Priority Substances Assessment Program and Screening Assessment Reports. from <u>http://www.hc-sc.gc.ca/ewh-semt/pubs/contaminants/index-eng.php#existsub</u>.
- International Agency for Research on Cancer (IARC). "Complete List of Agents evaluated and their classification." from <u>http://monographs.iarc.fr/ENG/Classification/index.php</u>.
- Minnesota Department of Health (MDH). (2011). MDH Health Risk Assessment Methods to Incorporate Human Equivalent Dose Calculations into Derivation of Oral Reference Doses.
- National Toxicology Program. from <u>http://ntp.niehs.nih.gov/?objectid=25BC6AF8-BDB7-CEBA-F18554656CC4FCD9</u>.
- National Toxicology Program (NTP) (1991). Developmental Toxicity of Naphthalene (CAS No. 91-20-3) in Sprague-Dawley Rats. U.S. Department of Health and Human Services, Public Health Service and National Institutes of Health.
- National Toxicology Program (NTP) (1992a). Final Report on the Developmental Toxicity of Naphthalene (CAS No. 91-20-3) in New Zealand White Rabbits. U.S. Department of Health and Human Services, Public Health Service and National Insitutes of Health.
- National Toxicology Program (NTP) (1992b). "Toxicology and Carcinogenesis Studies of Naphthalene (CAS No. 91-20-3) in B6C3F1 Mice (Inhalation Studies) - abstract only." <u>Natl Toxicol Program Tech</u> <u>Rep Ser</u> **410**: 1-172.
- National Toxicology Program (NTP) (2000). "Toxicology and carcinogenesis studies of naphthalene (cas no. 91-20-3) in F344/N rats (inhalation studies) abstract only." <u>Natl Toxicol Program Tech Rep Ser(500)</u>: 1-173.
- Shopp, G. M., K. L. White, Jr., et al. (1984). "Naphthalene toxicity in CD-1 mice: general toxicology and immunotoxicology." <u>Fundam Appl Toxicol</u> **4**(3 Pt 1): 406-419.

- Syracuse Research PhysProp Database. from <u>http://www.syrres.com/what-we-do/databaseforms.aspx?id=386</u>.
- The International Programme on Chemical Safety. "Chemicals Assessment." from <u>http://www.who.int/ipcs/assessment/en/</u>.
- Toxicology Excellence for Risk Assessment ITER "International Toxicity Estimates for Risk (ITER)." from http://iter.ctcnet.net/publicurl/pub_search_list.cfm.
- U.S. Environmental Protection Agency DRAFT IRIS Toxicological Review. (2004). "Naphthalene." from <u>http://cfpub.epa.gov/ncea/iris_drafts/recordisplay.cfm?deid=84403</u>.
- U.S. Environmental Protection Agency Health Effects Assessment Summary Table (HEAST) (July 1997).
- U.S. Environmental Protection Agency IRIS. "Integrated Risk Information Systems (IRIS) A-Z List of Substances." from <u>http://cfpub.epa.gov/ncea/iris/index.cfm?fuseaction=iris.showSubstanceList</u>.
- U.S. Environmental Protection Agency National Center for Environmental Assessment. from http://cfpub.epa.gov/ncea/cfm/archive_whatsnew.cfm.
- U.S. Environmental Protection Agency Office of Drinking Water. "2006 Edition of the Drinking Water Standards and Health Advisories." from <u>http://www.epa.gov/waterscience/criteria/drinking/dwstandards.pdf</u>.
- U.S. Environmental Protection Agency Office of Pesticide Programs Reregistration Status. "Pesticide Registration Status." from <u>http://www.epa.gov/pesticides/reregistration/status.htm</u>.
- U.S. Environmental Protection Agency Regional Screening Tables. "Mid-Atlantic Risk Assessment -Regional Screening Table." from <u>http://www.epa.gov/reg3hwmd/risk/human/rb-</u> <u>concentration_table/index.htm</u>.
- U.S. Environmental Protection Agency Toxicity and Exposure Assessment for Children's Health (TEACH). from <u>http://www.epa.gov/teach/</u>.
- U.S. Environmental Protection Agency Voluntary Children's Chemical Evaluation Program (VCCEP). "VCCEP Chemicals." from <u>http://www.epa.gov/oppt/vccep/pubs/chemmain.html</u>.
- U.S. Environmental Protection Agency (EPA) (2003). Health Effects Support Document for Naphthalene. Office of Water - Health and Ecological Criteria Division.
- U.S. Geological Survey Health-Based Screening Levels. from <u>http://infotrek.er.usgs.gov/apex/f?p=HBSL:HOME:0</u>.
- World Health Organization Guidelines for Drinking-Water Quality. (2008). from http://www.who.int/water_sanitation_health/dwq/gdwq3rev/en/index.html.